A major component of the population of people who have epilepsy are people with a learning disability. As a group, such individuals often have complex epilepsy which is refractory to treatment. Current available measures to assess the outcomes of therapeutic interventions in epilepsy are based on seizure frequency, seizure severity and quality-of-life measures, but have not been validated in people with a learning disability. Thus, we do not know if such measures of outcome serve the needs of this group. This review examines how able we are to assess the efficacy of our interventions to control epilepsy in people with learning disability. It is suggested that a standard data set is necessary as the basis of the assessment of any therapeutic intervention. Central components of this data set would encompass a definition of important characteristics of an individual, a description of their epilepsy and an assessment of the impact of their condition on both their own and their carer's health. The approach to obtaining this information should employ a methodology which can allow for environmental influences.
INTRODUCTION
As a result of complex associations with social stigma, psychological distress and physical morbidity, epilepsy and its manifestations demand the highest quality of care from a broad range of health, and other, professionals'. Assessing the quality of care and, more specifically, the outcomes of care interventions has become a major focus for all health services, and epilepsy services are no different. Central to this drive in the UK is the Cochrane collaboration, or clinical effectiveness campaign, which aims to encourage health services and practitioners to use interventions which are of proven efficacy. Epilepsy management and, in particular, pharmacological interventions have largely been assessed within the criteria of clinical effectiveness. The double-blind randomized controlled trial, the gold standard in the Cochrane approach, is now the norm for new phannacotherapies, particularly when comparing these with more established treatments.
Outcomes used in these trials are normally: (1) seizure, (2) drop out and (3) side-effect frequency.
Increasingly, broader social outcomes are accepted through a range of quality-of-life measures. The validity of these measures in the population of people with learning disability is not established*.
People with learning disability are a major component of the population of people with epilepsy who receive specialist care3, yet they do not fit well into these established evaluation processes. This can be seen by the paucity of randomized controlled trialswith a continued trend to open trials and retrospective case-note evaluations.
It may be that the complexity of study design in a population with this range of additional needs, namely: (1) communication difficulties, (2) increased morbidities such as epilepsy and behavioural disorders and (3) increased care needs for activities of daily living, has hindered the development of trials. This review will focus on the establishment of outcome measures for the management of epilepsy through an assessment of: (1) the characteristics of epilepsy, (2) the theory and measurement of outcome and (3) outcome standards in research and practice in people with a learning disability. People with a learning disability are defined by intelligence quotient (IQ < 70), reduced adaptive skills and age of onset in the developmental period, before the age of 18 years (DSM IV). These broad characteristics allow for considerable variation between individuals, yet allow us to approach general themes which apply to the population as a whole. Key differences can be seen in the epidemiology of the epilepsy, the seizure type, the prevalence of certain epilepsy syndromes and the outcome of treatment. When addressing individuals, important interindividual variation can be influenced by the aetiology of the condition, the degree of learning disability, the presence of additional impairments, medication, and environmental factors.
Epidemiology
As is often the case, the prevalence of a particular illness in populations of people with learning disability is dependent on both the source and age of the sample population. A survey in an institution for people with learning disability gave a prevalence of 32%4, while a large community-based questionnaire survey of health needs in people with a learning disability reported a prevalence of 22.1%, making epilepsy second only to psychological illness as a comorbidity5. This can be compared with an estimate of the prevalence of epilepsy in the general population of between 0.4 and 1 %6.
Seizure type, frequency and control
In comparison with the population of people with epilepsy as a whole, people with a learning disability who also have epilepsy exhibit different types and frequencies of seizures and have a higher frequency of certain epilepsy syndromes. Epidemiologically based data on seizure type in the adult population with a learning disability is somewhat hampered by definition and sampling, though the picture described in the adult-outpatient survey of Tobias et al3 of a relative increase in unclassifiable and atonic seizures would seem to reflect clinical experience. As well as this association with ah increase in single-seizure types there is an increase in seizure syndromes, in particular the Lennox-Gastaut syndrome4. Seizure control is difficult to achieve in this patient group. This was confirmed in an audit of a large epilepsy clinic in Glasgow3 which showed that attendees with leaming disability were significantly less likely to attain seizure control than their non-learning-disabled counterparts.
Individual characteristics
A consequence of the grouping of populations is that it can lead to a diminution of our recognition of the important influences of individual characteristics within the group. This is particularly important in people with a learning disability who are a heterogeneous population. These individual features have a major part to play in both the seizure disorder suffered by the individual and the expected response to treatment. Some individual characteristics influencing the outcome are listed in Table 1 . Three factors emerge as having a specific influence on outcome: the aetiology of the disability, the degree of learning disability and the presence of other impairments.
Aetiologic factors
The underlying cause of the learning disability may have an impact on seizure type and outcome. The seizure disorder associated with some conditions, for example tuberous sclerosis7, has been well defined.
In the case of tuberous sclerosis the value of a good epidemiological survey was shown as this indicated a lower-than-expected prevalence of learning disability in the condition than previously recognized. The nature of epilepsy in Down's syndrome has been well characterized' where seizure disorder is often associated with Alzheimer's disease, particularly if onset occurs at over 30 years of age. This obviously has a significant impact on the outcome of new-onset epilepsy.
For some other conditions associated with disability, such as the Fragile X syndrome, epilepsy conditions specific to the syndromes have been suggested. There are reports that a specific EEG abnormality similar to benign childhood epilepsy with centrotemporal spikes is present'. In this case there remains controversy over the validity of the finding-possibly due to sampling and other methodological issues".
In a large epidemiological survey of childhood epilepsy and learning disability, Steffenberg and colleagues' ' were able to ascertain the relative importance of pre-and perinatal influences on an individual developing seizures. The study showed a higher risk of seizure disorder for individuals with a perinatal cause of their learning disability as compared with chromosomal abnormalities.
Degree of learning disability
The close association between the severity of leaming disability and the severity of the seizure disorder is a truism of epilepsy care. The published evidence supports this view. Epidemiological evidence from the Camberwell studies of Corbett" showed an increasing prevalence of epilepsy with decreasing intellectual functioning; a lifetime prevalence of 30% in children with IQ < 50 and of 50% with IQ < 20. The study by Steffenberg et al " showed a prevalence of active epilepsy in 6-13-year-olds of 0.7%0 for mild learning disability and 1.3%0 for severe learning disability.
Ofher impairments and medication
The association between the likelihood of having epilepsy if an individual has an additional impairment is strong. Hauser l3 showed an increased risk of epilepsy from 11 to 48% when a child with leaming disability also had cerebral palsy; an association confirmed by others . l4 Steffenburg and colleagues" showed a prevalence of cerebral palsy of 14 and 59%, respectively, in the mild and severe groups of patients with learning disability and epilepsy. The severe group had a greatly increased risk of additional visual impairment of 3% in the mild and 37% in the severe population of people with learning disability who had epilepsy.
Major co-morbidities such as psychiatric and or severe behavioural conditions should be recognized, with an estimated community prevalence of 32.2%'. The interaction between behaviour and epilepsy is complex, and leads to two main confounders; first, the ability to confuse behaviours not associated with epilepsy as epilepsy-related and, secondly, the effect of prescription of antipsychotic medication, due to their known epileptogenic potential. Many studies have looked at the prevalence of antipsychotic medication in populations of people with learning disability15. Prevalence figures range from 40.2% in hospitals to 19.3% in the community and 10.1% in family homes.
Finally, the issue of polypharmacy with antiepileptic medication may also influence outcome. While in the general population there remains a view that monotherapy is the gold standard for epilepsy treatment, the complexity of epilepsy in people with a learning disability may have led to the high prevalence of polytherapy in this population with estimates of 33% of patients on two anticonvulsants and 4% on three16. True clinical effectiveness data does not exist to clarify the true effect of polytherapy on outcome in this population.
Environmental influences
The context of care of people with a learning disability is varied. While most countries are moving at differing rates toward a community-care-based service, an individual's residence may range from a 20-bedded hospital ward to an individual flat in the community. His or her carers could be elderly parents or constantly changing paid carers. These variations in environmental contexts are known to influence many aspects of the lives of people with learning disability such as the expression of behavioural disturbance, the amount of social integration and other activities17. Other key environmental factors will be the health of the carers and the quality of the carer-patient interaction.
THE THEORY AND MEASUREMENT OF OUTCOME IN PEOPLE WITH A LEARNING DISABILITY
Much work has been performed in the population of people with learning disability as a whole in an attempt to produce a unified concept of outcome. Central to this has been the concept of quality of life, from which obvious parallels may be drawn to themes in epilepsy research. As in the general epilepsy field, quality of life remains an elusive concept in disability, with many conceptual levels covering factors such as objective life conditions, subjective feelings of well-being and personal values. The work of Felce and Perry '* has attempted to place a cohesive structure and develop a standardized approach to the issue. They have suggested that quality of life may be considered in terms of effects on a range of areas, such as physical well-being, material well-being, social well-being, development, activity and emotional well-being.
Of particular importance is the impact of epilepsy on the family. Unfortunately we know little about the precise impact of epilepsy on families of individuals who have epilepsy and learning disability. However, there exist important pointers from workers who have looked at the impact of caring individuals with disability. The work of Todd and Sheam" has given pointers. They recount through interviews with parents of 33 co-resident individuals with disability that time, socialization and services which did not reflect their needs were of particular importance.
As in generic-quality-of-life measures the usual methodology has remained questionnaire based. Questionnaire methodology is clearly hampered by the individuals communication difficulties and is therefore usually directed to carers. Unfortunately no reliable global measure of quality of life has been established. Good measures do exist to measure some co-morbidities in particular traits such as behaviour disturbance*. Other methodologies have been applied to assess the outcome of interventions in people with a learning disability. Probably the most sensitive and responsive to the assessment of an individual's activity in his/her ordinary setting has been the application of computerized direct observation methodology.
Direct observation of patients through computer and video monitoring also has potential in measuring outcomes in patients with learning disability and epilepsy. Unlike informant-based ratings which are notoriously unreliable, this technique has the advantage of allowing for objective and reliable measurement of behaviour. It also allows the direct assessment of environmental effects on behaviour and, through the use of video recordings, often detects behaviours that go unnoticed by carers. Data may be directly entered onto a computer, making the analysis of behaviour much quicker, simpler, and less susceptible to bias.
As with most systems, there are a few disadvantages. These include obtaining only snapshots of behaviour, the process may be time consuming, people must be trained to use the equipment, and data reliability must be continually checked.
This approach to patient assessment appears, therefore, to provide good direct information on patient behaviour in the home, and has the added advantage of removing biases which can so often influence reporting by parents and carers.
The application of direct observation has generally been in the context of assessing an individual's interactions and activities in various community or hospital settingst7**0
Generic outcome measures
The validity of generic epilepsy outcome measures has been reviewed elsewhere*. In summary, outcomes for epilepsy interventions may be divided into three broad areas. First, there is the seizure-related outcome which is dependent on seizure count; this usually subdivides into 'seizure free' or '> 50% reduction in seizure count'. Secondly, side-effect related, which is usually assessed by either (i) reported adverse effects or (ii) drop out from a trial. It should be noted, however, that while the latter approach (i.e. recording drop out rate) is considered to measure the acceptability of a treatment, it may of course reflect lack of efficacy. Thirdly, quality-of-life related; an increasingly large body of literature exists in this area*'. These measures are usually patient-experience based though they may also include other family members or health professionals.
OUTCOME STANDARDS IN RESEARCH AND PRACTICE
Drawing together the themes we have discussed so far there remain two questions, namely: What should we measure? and How should we measure it?
In this section we will focus on the key components to methodology. The precise measurement scales used will be discussed elsewhere'. The.first step in actively implementing a standard methodology involves defining the individual patient. This may be approached by assessment of several variables, including ability, personal attributes, aetiology and seizure syndrome. It is recommended that standard data sets are used to describe aetiology and seizure type. Validity of diagnosis and comparability between groups will be greatly helped by this.
The second step involves the use of measures, which are sensitive to change, used to determine the efficacy of a treatment in a specific patient. In both research and practice the measurement of an appropriate baseline is essential. Appropriate measures include seizure frequency (which may be recorded on a seizure chart), behaviour (monitored by a scale such as the Aberrant Behaviour Checklist), social interaction, patient independence, contact and participation (assessed by direct observation), and general wellbeing (monitored on a global scale involving the targeting of certain baselines such as sleep or appetite, or a parent OF carer's view of how the patient is and whether a certain variable has changed over time).
The third area is the measurement of the effect of the patient's epilepsy on the carers. It is hard to give precise guidance here. It is an important issue and the development of scales based on carers experiences will be useful. In the absence of validated epilepsyrelated scales, generic quality-of-life measures such as the SF36 could be used or specific-trait measures such as the Beck depression inventory, though we 335 must be careful that we do not inappropriately apply pathology to the role of the carer.
Figure one illustrates how such measures may be applied in either research or clinical settings.
CONCLUSION
Currently available measures to assess the outcomes of therapeutic interventions on epilepsy in people with learning disability are often inappropriate and/or have not been validated in this patient group. In order to adequately assess the impact of therapeutic intervention in these patients we have suggested a standard methodology and outcome measures that may be used to improve management. The outcome measures should be sensitive to change, include information on individual characteristics and allow for variables such as treatment compliance and environmental confounders. In addition, new technologies, such as direct observation (through computer systems and video recordings) appear to have much potential and should be considered as effective tools in minimizing bias and providing direct, quick and 'reliable assessment of behaviour.
Of course these suggestions may not be fully inclusive and other outcome measures, which may include a reduction in polypharmacy, reduced hospital care, improved carer education and client satisfaction, may be considered. In addition to implementation of the above tools, delivery of these outcome measures may be achieved through a number of initiatives, including clinical audits, training programmes' on epilepsy and polypharmacy, specific clinics, patient surveys, administrative support, and care-group task forces and business plans which enlist the support of a range of professionals in the field (e.g. Chief Executives, Clinical Directors, Business Managers, Psychiatrists, Clinical Nurse Specialists, General Practitioners).
While several needs remain to be met (for example, developing a sufficiently sensitive assessment scale) we believe that outcome monitoring may be significantly improved in this the most challenging of patient groups, by actively implementing at least some of the measures described above.
